Ultragenyx Pharma (RARE) Reports Q4 Loss of $0.37 on Revenues of $91.54M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
UPDATE: Ultragenyx Pharma (RARE) Sees Intra-Day Weakness
February 10, 2021 10:38 AM EST(Updated - February 10, 2021 10:43 AM EST)
Ultragenyx Pharma (NASDAQ: RARE) sees mid-day weakness, shares down 1.7%.
UPDATE: Weakness said related to FDA FAERS database showing Dojolvi drug has lead to several recent deaths.
... More